Table 3:
Overall survival by risk group in the training and validation datasets.
| Score | n (%) | Comparison | Hazard Ratio (95% CI) | 24 Month OS (95% CI) | C-statistic (95% CI) | log-rank p-value | |
|---|---|---|---|---|---|---|---|
| Ibrutinib/CIT Training Dataset1 | n=727 | 0·74 (0·60–0·85) | <0001 | ||||
| Low | 0–1 | 278(38·2%) | — | — | 89·7% (85·4–92·7) | ||
| Intermediate | 2–3 | 321 (44·2%) | vs Low | 2·38 (1·65–3·45) | 79·5% (74·5–83·6) | ||
| High | 4 | 82 (11·3%) | vs Intermediate | 2·22 (1·56–3·16) | 55·8% (44·1–65·9) | ||
| vs Low | 5·29 (3·44–8·15) | ||||||
| Missing | — | 46 (6·3%) | — | — | |||
| Ibrutinib/CIT Internal-Validation2 | n=242 | 0·79 (0·56–0·97) | <0001 | ||||
| Low | 0–1 | 96 (39·7%) | — | — | 92·0% (83·9–96·1) | ||
| Intermediate | 2–3 | 119 (49·1%) | vs Low | 2·78 (1·45–5·33) | 76·4% (67·5–83·2) | ||
| High | 4 | 27 (11·2%) | vs Intermediate | 1·83 (1·00–3·33) | 66·7% (45·7–81·1) | ||
| vs Low | 508 (2·38–10·85) | ||||||
| Idelalisib/CIT External-Validation1 | n=897 | 0·71 (0·59–0·81) | <0001 | ||||
| Low | 0–1 | 278 (31·0%) | — | — | 82·6% (77·1–86·9) | ||
| Intermediate | 2–3 | 460 (51·3%) | vs Low | 2·71 (1·96–3·73) | 61·8% (56·9–66·4) | ||
| High | 4 | 147 (16·4%) | vs Intermediate | 1·44 (1·10–1·89) | 49·5% (40·7–57·8) | ||
| vs Low | 3·90 (2·71–5·62) | ||||||
| Missing | — | 12 (1·3%) | — | — | |||
| Venetoclax/CIT External-Validation1 | n=389 | 0·76 (0·66–0·85) | 001 | ||||
| Low | 0–1 | 170 (43·7%) | 951% (90·5–97·5) | ||||
| Intermediate | 2–3 | 180 (46·3%) | vs Low | 201 (1·14–3·56) | 84·6% (78·1–89·2) | ||
| High | 4 | 30 (7·7%) | vs Intermediate | 1·40 (0·65–3·02) | 82·2% (62·5–92·2) | ||
| vs Low | 2·82 (1·23–6·50) | ||||||
| Missing | — | 9 (2·3%) | |||||
| MCCD External-Validation1 | n=220 | 0·61 (0·56–0·66) | <0001 | ||||
| Low | 0–1 | 62 (28·2%) | — | — | 87·5% (79·2–96·6) | ||
| Intermediate | 2–3 | 149 (67·6%) | vs Low | 2·95 (1·80–4·84) | 63·5% (56·0–72·1) | ||
| High | 4 | 9 (4·1%) | vs Intermediate | 2·02 (0·93–4·40) | 44·4% (21·4–92.3) | ||
| vs Low | 5·96 (2·46–14·41) |
OS, overall survival; CI, confidence interval; CIT, chemoimmunotherapy; MCCD, Mayo Clinic CLL Database;
1
Based on complete case analysis.
2
Based on multiple imputation analysis (imputed dataset whose C-statistic is the median of the 5 imputations is shown).